title: Effect of probiotics on aspirin-induced gastric mucosal lesions.
abstract: OBJECTIVE
  We aimed to investigate the role of a probiotic mixture, including 13 different bacteria, in the prevention of aspirin-induced gastric mucosal injury.
  
  
  METHODS
  Forty rats were allocated into 4 groups: normal control, aspirin, probiotic control, and probiotic plus aspirin. Normal control and aspirin groups received 0.2 ml of skim milk by daily gavage for 14 days. Probiotic control and probiotic plus aspirin groups were administered 0.2 ml/day of probiotic mixture (1.3 x 10(10) cfu/ml) suspended in skim milk by daily gavage for 14 days. On day 15, gastric lesions were induced by administration of aspirin (200 mg/kg) in the aspirin and probiotic plus aspirin groups. Normal control and probiotic control groups were given saline.
  
  
  RESULTS
  Pretreatment with probiotic mixture reduced aspirin-induced gastric damage scores (4.50 ± 0.43 and 2.60 ± 0.40, p<0.01) and exerted tendency of downregulation of proinflammatory cytokines elicited by aspirin (p>0.05). We also found that the probiotic mixture increased sIgA production approximately 7.5-fold in the stomach, and significantly reduced the malondialdehyde (MDA) increase in the gastric mucosa elicited by aspirin (p<0.001). Additionally, pretreatment with the probiotic mixture alleviated aspirin-induced reduction of mast cell count in the gastric mucosa.
  
  
  CONCLUSIONS
  Probiotic mixture pretreatment attenuates the aspirin-induced gastric lesions by reducing the lipid peroxidation, enhancing mucosal sIgA production, and stabilizing mucosal mast cell degranulation into the gastric mucosa.
authors.affiliation: Department of Gastroenterology, Süleyman Demirel University, School of Medicine, Isparta. senolaltug@gmail.com
authors.forename: Altuğ
authors.initials: A
authors.lastname: Senol
authors.forename: Mehmet
authors.initials: M
authors.lastname: Işler
authors.forename: Aynur G
authors.initials: AG
authors.lastname: Karahan
authors.forename: Gülden B
authors.initials: GB
authors.lastname: Kiliç
authors.forename: Hakan
authors.initials: H
authors.lastname: Kuleaşan
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Gören
authors.forename: Ulkü
authors.initials: U
authors.lastname: Saritaş
authors.forename: Selçuk
authors.initials: S
authors.lastname: Kaya
authors.forename: Metin
authors.initials: M
authors.lastname: Cırış
authors.forename: Onur
authors.initials: O
authors.lastname: Aktürk
authors.forename: Buket C
authors.initials: BC
authors.lastname: Aridoğan
authors.forename: Hilmi
authors.initials: H
authors.lastname: Demırın
authors.forename: Lütfü M
authors.initials: LM
authors.lastname: Cakmakçi
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity*; D001241:Aspirin / Q000633:toxicity*; D015550:Cell Degranulation / Q000187:drug effects; D005751:Gastric Lavage; D005753:Gastric Mucosa / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D007070:Immunoglobulin A / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008407:Mast Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D019936:Probiotics / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007070:Immunoglobulin A; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D001241:Aspirin